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Abstract
BCA2 (Rabring7, RNF115 or ZNF364) is a RING-finger E3 ubiquitin ligase that was identified as a co-factor in the restriction
imposed by tetherin/BST2 on HIV-1. Contrary to the current model, in which BCA2 lacks antiviral activity in the absence of
tetherin, we found that BCA2 possesses tetherin-independent antiviral activity. Here we show that the N-terminus of BCA2
physically interacts with the Matrix region of HIV-1 and other retroviral Gag proteins and promotes their ubiquitination,
redistribution to endo-lysosomal compartments and, ultimately, lysosomal degradation. The targeted depletion of BCA2 in
tetherin-expressing and tetherin-deficient cells results in a significant increase in virus release and replication, indicating that
endogenous BCA2 possesses antiviral activity. Therefore, these results indicate that BCA2 functions as an antiviral factor that
targets HIV-1 Gag for degradation, impairing virus assembly and release.
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Introduction
HIV-1, as well as other animal viruses, relies on the contributions
of cellular molecules to ensure virus replication [1]. Conversely,
mammalian cells have evolved mechanisms to block different stages
of the virus life-cycle, thereby suppressing virus production. These
proteins are generally known as restriction factors, and they provide
an early antiviral defense. Despite their antiviral activity, the
primate lentiviruses have developed mechanisms to circumvent
these cellular factors. The need to escape this first line of defense
seems to be an important driving force behind the acquisition of
these countermeasures, indicating that overcoming these proteins is
important for virus replication and infectivity [2,3,4].
So far, five potent restriction factors have been shown to
effectively block HIV and SIV replication: APOBEC3 members
(A3), TRIM5 proteins, Mx2/MxB, SAMHD1 and tetherin/BST2
[3,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19]. Tetherin, an interfer-
on-inducible transmembrane protein, impedes the release of
enveloped viruses from infected cells, by trapping nascent virions
to the cell surface [15,16,20]. However, the primate lentiviruses
have evolved different mechanisms to antagonize tetherin.
Whereas HIV-1 Vpu and HIV-2 Env counteract human tetherin
[15,16,21], we and others identified Nef as the protein used by
most SIVs to overcome non-human primate tetherin, and we
further characterized the mechanism of tetherin antagonism by
Nef [22,23,24,25,26].
A recent study [27], identified BCA2 (Breast Cancer-Associated
gene 2) –a RING-finger E3 ubiquitin ligase– as a co-factor in the
restriction imposed by tetherin on HIV-1, lacking antiviral activity
in cells not expressing tetherin. Miyakawa and collaborators
showed that BCA2 interacts with the cytoplasmic domain of
tetherin to facilitate the internalization and lysosomal degradation
of tethered virions, and that the E3 ligase activity of BCA2 is
dispensable to enhance tetherin-mediated restriction [27]. Con-
trary to this model, we found that BCA2 is also a tetherin-
independent antiviral factor. In particular, BCA2 reduces the
cellular levels of HIV-1 and other retroviral Gag proteins. In
contrast to the tetherin-dependent activity of BCA2, an intact
RING-finger domain is required for tetherin-independent restric-
tion. Consistent with this observation, the HIV-1 Gag protein, as
well as other retroviral Gag proteins, become ubiquitinated in cells
expressing BCA2. Immunoprecipitation assays showed that the N-
terminus of BCA2 interacts with HIV-1 Gag through its Matrix
region, and that mutation of a glycine at position 2 in Matrix,
which prevents the addition of a myristoyl group, abrogates this
interaction as well as Gag ubiquitination and degradation. We also
show that BCA2 promotes the lysosomal degradation of HIV-1
Gag. In agreement with this, and with the previously reported
association of BCA2 with Rab7 –a small GTPase associated with
lysosomal biogenesis [28]– cellular imaging analyses showed
extensive co-localization of HIV-1 Gag with endo-lysosomal
markers in cells expressing BCA2. The targeted depletion of
endogenous BCA2 in tetherin-expressing and tetherin-deficient
cells resulted in a significant increase in the release of virus
particles, and therefore, in virus replication, suggesting that
endogenous BCA2 has antiviral activity. Taken together, these
observations indicate that BCA2 poses a significant barrier in the
replication of HIV-1 and other retroviruses.
Results
BCA2 has tetherin-independent antiviral activity
To study the role of BCA2 in virus restriction, we examined the
effects of this protein on virus release in the presence and absence
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tetherin [15] (data not shown), were co-transfected with HIV-1
NL4-3, HIV-1 NL4-3 Dvpu, SIVmac239 or SIVmac239 Dnef
proviral DNA, along with constructs expressing either human or
rhesus macaque tetherin (hBST2 or rBST2), HA-tagged BCA2 or
empty vectors (Figure 1). Transfections were performed in
duplicate in 24-well plates, as described in the materials and
methods section, and were repeated independently three addi-
tional times. The accumulation of virus particles in the cell culture
supernatant was measured by HIV-1 p24 or SIV p27 antigen-
capture ELISA 48 hours post-transfection, as previously described
[22,25,29]. Since Vpu affords resistance to tetherin [15,16], the
restriction imposed by tetherin on virus release was significantly
higher on vpu-deleted HIV-1 than on wild-type HIV-1. In
agreement with previous observations [27], the antiviral activity
of tetherin –particularly on wild-type HIV-1– was enhanced in
cells expressing BCA2. Contrary to that report, a ,2.5-fold
reduction in virus release was detected from cells expressing
BCA2, even in the absence of tetherin (Figure 1A). To confirm
these observations, the cell lysates from these transfections, as well
as the virions present in the culture supernatants, were analyzed by
western blot (Figure 1B). Although we observed a reduction in the
amount of virion-associated p24 from cells expressing tetherin,
particularly for HIV-1 Dvpu virions, a slight increase in the
intracellular levels of p24 was detected, which likely reflects the
presence of virions tethered to the cell surface. In cells expressing
HA-BCA2, a significant decrease in the levels of virion-associated
p24 was observed for both wild-type HIV-1 as well as for HIV-1
Dvpu. This corresponded to a 4-fold reduction in the levels of
intracellular p24. Nevertheless, BCA2 did not result in significant
changes in the expression levels of other viral proteins, such as Nef
or Vpu. Intermediate levels of cellular p24 were detected in cells
co-expressing HA-BCA2 and tetherin, reflecting a defect in Gag
expression or processing in the presence of HA-BCA2, and the
restriction imposed by tetherin on trapping virions to the cell
surface.
To determine if the effect of BCA2 on Gag expression and/or
processing –and thereby on virus release– was specific for HIV-1,
we performed similar assays with SIVmac239, a closely related
lentivirus. Consistent with a role for Nef in tetherin antagonism
[22,23], the effects of tetherin on particle release were more
pronounced in nef-deleted SIV than in wild-type virus (Figure 1C).
Similar to HIV-1 NL4-3, expression of HA-BCA2 resulted in a
,2.5-fold reduction in the amount of virus particles present in the
culture supernatant (Figure 1C). These observations were also
corroborated by western blot, where a decrease in cellular and
virion-associated p27 was detected in cells expressing HA-BCA2
(Figure 1D), which is consistent with the data obtained for HIV-1
NL4-3. Therefore, BCA2 has tetherin-independent antiviral
activity, which results in a defect in either Gag expression or
processing, impairing virus assembly and release for both HIV-1
and SIV.
To better study the antiviral effects of BCA2, a titration curve
was performed by co-transfecting 293T cells with increasing
concentrations of a construct encoding HA-BCA2 and proviral
DNA for wild-type HIV-1 NL4-3 or SIVmac239. Differences in
DNA concentrations were offset by the addition of empty vector.
Virus release was measured by HIV-1 p24 or SIV p27 antigen-
capture ELISA and expressed as the percentage of maximal virus
release in the absence of HA-BCA2. Consistent with the data
presented in Figure 1A and 1C, increasing concentrations of the
full-length BCA2 protein resulted in a dose-dependent reduction
in virus release for both HIV-1 NL4-3 and SIVmac239 (Figure 1E;
solid lines). Accordingly, a defect in cellular Gag expression was
observed for both lentiviruses, but no defect in the expression
levels of other viral proteins (Vpu, Nef or Env) was observed,
indicating that the antiviral effects of BCA2 specifically target Gag
(Figure 1F). Conversely, HA-BCA2 did not affect virus release nor
infectivity for influenza virus H1N1 PR8, indicating that the
antiviral activity of BCA2 may not be of broad range (Figure 1E,
black line). To further characterize the mechanism of activity of
BCA2, another titration curve was performed with a ligase-dead
mutant of BCA2 (DRing BCA2). In this case, no reduction in virus
release was observed for either HIV-1 NL4-3 or SIVmac239
(Figure 1E; dashed lines). In accordance with these results, no
defect in Gag expression or processing was detected either
(Figure 1G). Therefore, the antiviral effects of BCA2 require an
intact RING-finger domain.
To rule out that the effects of BCA2 on Gag expression and
virus production are not the result of artifacts due to protein
overexpression, virus release assays for HIV-1 NL4-3 and
SIVmac239 were performed in the presence of an irrelevant
protein to the virus replication cycle (CD8-STOP). Since BCA2 is
connected to the endo-lysosomal pathway through interactions
with Rab7 [28], wild-type Dynamin 2 (Dyn2) was also included in
these assays to test for proteins that may accelerate the rate of
endocytosis. Consistent with the data shown in Figure 1, only cells
expressing HA-BCA2 showed defects in virus release (Figure S1A-
S1C). Additionally, we used a BCA2-specific antibody to compare
the levels of ectopic HA-BCA2 relative to endogenous BCA2 in an
additional titration curve for HIV-1 NL4-3. HA-BCA2 was
expressed to a similar extent as endogenous BCA2 in transfections
with 50 ng of the HA-BCA2 construct. At this concentration,
there was already a noticeable effect on Gag expression and virus
release (Figure S1D). Therefore, the decreased levels of Gag and
virus production observed in cells expressing HA-BCA2 are not
the result of artifacts due to protein overexpression.
The effects of BCA2 on virus release were also examined in an
infectivity assay. 293T cells were co-transfected with HIV-1 NL4-3
or SIVmac239 proviral DNA in the presence and absence of HA-
BCA2. Forty-eight hours post-transfection, virions accumulated in
the culture supernatant were collected and used to infect the
reporter GHOST X4/R5 cell line, which is stably transduced with
a tat-inducible GFP reporter vector. The percentage of GFP
+ cells
was determined by FACS, and the infectivity of viruses produced
from cells expressing HA-BCA2 relative to those produced from
parental 293T cells was calculated (Figure S2A). These experi-
Author Summary
Tetherin (also known as BST2, CD317 or HM1.24) is an
interferon-inducible cellular factor that interferes with the
release of enveloped viruses from infected cells. A recent
study identified BCA2 (Breast Cancer-Associated gene 2,
also known as RNF115, ZNF364 or Rabring7), a RING-finger
E3 ubiquitin ligase, as a co-factor in the tetherin-mediated
restriction of HIV-1. According to this model, BCA2
interacts with sequences in the N-terminus of tetherin to
promote the internalization and lysosomal degradation of
tethered HIV-1 particles, with no apparent antiviral activity
in cells not expressing tetherin. However, here we show for
the first time that BCA2 inhibits virus production for HIV-1
and other retroviruses in a tetherin-independent manner
by reducing the cellular levels of Gag – the precursor of
the structural proteins Matrix, Capsid, Nucleocapsid and
p6. Hence, contrary to its reported role as a tetherin co-
factor, BCA2 functions as a tetherin-independent antiviral
factor that impairs virus assembly and release.
BCA2 Has Intrinsic Anti-HIV Activity
PLOS Pathogens | www.plospathogens.org 2 May 2014 | Volume 10 | Issue 5 | e1004151BCA2 Has Intrinsic Anti-HIV Activity
PLOS Pathogens | www.plospathogens.org 3 May 2014 | Volume 10 | Issue 5 | e1004151ments were independently repeated in duplicate two additional
times. Consistent with the virus release data, the amount of
infectious particles produced from HA-BCA2-expressing cells was
considerably reduced. The cell lysates and virions produced from
these cells were also analyzed by western blot, confirming a
substantial reduction in the levels of virion-associated capsid from
cells expressing HA-BCA2 (Figure S2B). Therefore, BCA2
significantly decreases the offspring of infectious virions.
To explore if BCA2 exclusively targets lentiviral Gag proteins,
we performed experiments with Mo-MLV, a gammaretrovirus. 293T
cells were co-transfected with Mo-MLV proviral DNA along with
constructs coding for HA-BCA2, the ligase-dead BCA2 mutant
(DRing BCA2), tetherin as a positive control for restriction or
empty vector. Transfections were performed in duplicate in three
independent experiments, as explained above. Virus release for
Mo-MLV was measured by MuLV p30 core antigen ELISA of the
culture supernatant 48 hours post-transfection, and expressed as
the percentage of maximal virus release in the absence of tetherin
or HA-BCA2. In agreement with previous reports, tetherin
imposed a significant barrier to the release of Mo-MLV virions
[30]. Similar to HIV-1 and SIV, virus release was significantly
impaired for Mo-MLV in cells expressing HA-BCA2, and no
significant effects on virus release were observed in the presence of
DRing BCA2 (Figure S3A). These results were confirmed by
western blot, where a decrease in the expression levels of cellular
Gag and virion-associated core protein p30 was detected in HA-
BCA2-expressing cells (Figure S3B).
Identification of residues in BCA2 required for antiviral
activity
To define amino acids in BCA2 that contribute to antiviral
activity, we introduced point mutations at important residues in
BCA2, such as the E3 catalytic domain (C228C231), ubiquitination
sites (K26K32) and phosphorylation sites (S132S133) [31]
(Figure 2A). These mutants along with wild-type BCA2 were tested
in three independent virus release assays for their antiviral activity
against HIV-1 NL4-3, SIVmac239 and Mo-MLV, as previously
described. Consistent with our initial observations, there was a ,3-
fold reduction in the amount of virus particles released into the
culture supernatant of cells expressing wild-type HA-BCA2.
Mutations in residues that are susceptible to become ubiquitinated
aswellasAKT-phosphorylated didnotaffectthe antiviral activityof
BCA2. However, mutations in the catalytic RING-finger domain
resulted in the inability of BCA2 to inhibit virus release for these
retroviruses (Figure 2B, upper panel). These observations were
corroborated by western blot, where a decrease in cellular Gag and
virion-associated capsid (CA) is only observed in the presence of
BCA2, or functional BCA2 mutants (Figure 2B, bottom panel).
Therefore, unlike the tetherin-dependent activity of BCA2, the E3
ligase activity is required for tetherin-independent restriction. To
separate the tetherin-dependent (non-RING domain requiring)
from the tetherin-independent (RING domain requiring) antiviral
activity of BCA2, we performed additional assays in parental 293T
cells and 293T cells stably expressing tetherin, where wild-type
BCA2 and the ligase-dead mutants were tested for their antiviral
activity. In contrast to Miyakawa’s results [27], no enhancement in
virus restriction was detected in the presence of tetherin and the
RING-defective mutants, indicating that the reduction in virus
release observed in the presence of HA-BCA2 and tetherin -likely
reflects a synergistic effect of the antiviral properties of both proteins
(Figure 2C). Therefore, our results suggest that the antiviral activity
of BCA2 is mainly tetherin-independent.
BCA2 promotes the ubiquitination of HIV-1 Gag and
other retroviral Gag proteins
Since the E3 ligase activity of BCA2 is required for antiviral
activity, we hypothesize that the mechanism by which BCA2
impairs the expression of Gag requires Gag ubiquitination. To test
this, we performed polyubiquitination assays. 293T cells were co-
transfected with HIV-1, SIV and Mo-MLV Gag constructs in the
presence and absence of HA-BCA2. Cell lysates were incubated
with a polyubiquitin affinity resin (Thermo Scientific). After
several washing steps, the bound fraction was eluted and analyzed
by western blot. Retroviral Gag proteins were found to bind the
polyubiquitin affinity resin only in the presence of HA-BCA2,
suggesting that BCA2 promotes their ubiquitination (Figure 3A).
As a control, HA-BCA2 was also detected in the eluted fraction,
since BCA2 has auto-ubiquitination activity [32]. However, its
ubiquitination levels were variable in these samples, although the
input levels of HA-BCA2 were similar across the assay (Figure 3A).
This may reflect a previously reported characteristic of the E3
ligase activity of BCA2 in substrate ubiquitination versus auto-
ubiquitination, where the auto-ubiquitination activity of BCA2
increases in the absence of target proteins susceptible to become
ubiquitinated [33]. This is consistent with the fact that the lower
levels of ubiquitinated HA-BCA2 are found in the presence of the
Gag protein showing more binding to the polyubiquitin affinity
resin (SIV Gag). However, more ubiquitinated HA-BCA2 is found
in the presence of HIV-1 Gag, which bound less efficiently to the
resin. These observations were corroborated in two additional
independent experiments.
Although these results indicated that Gag proteins become
ubiquitinated in the presence of BCA2, their electrophoretic
pattern did not match with the profile of ubiquitinated proteins,
which normally display a characteristic smear. Since BCA2 has
auto-ubiquitination activity, the presence of Gag proteins in the
pulled-down fraction may be due to indirect effects on Gag-BCA2
association. To further investigate if Gag undergoes ubiquitination
by BCA2, we performed immunoprecipitation assays in which
retroviral Gag proteins were pulled-down in the presence and
Figure 1. BCA2 has tetherin-independent antiviral activity. The antiviral activity of BCA2 was tested by co-transfecting 293T cells in duplicate
with HIV-1 NL4-3, HIV-1 NL4-3 Dvpu, SIVmac239 or SIVmac239 Dnef proviral DNA in the presence of constructs coding for human or rhesus tetherin
(hBST2, rBST2), HA-BCA2 or empty vector. Differences in DNA concentrations were offset by the addition of empty vector, and results were confirmed
in three additional independent experiments. (A) Virus release for HIV-1 was measured by p24 antigen-capture ELISA 48 hours post-transfection. (B)
The whole cell lysates (WCL) and virions generated from these transfections were analyzed by western blot to assess the expression levels of tetherin,
HA-BCA2 and viral proteins (Nef, Vpu, Gag, CA: p24). (C) Virus release for SIV was assessed by p27 antigen-capture ELISA. (D) The expression levels of
tetherin, HA-BCA2 and viral proteins were also assessed by western blot (Nef, Gag, CA: p27). (E) 293T cells were co-transfected with equal amounts of
HIV-1 or SIV proviral DNA and increasing concentrations of expression vectors coding for HA-BCA2 or DRing BCA2. Differences in DNA concentration
were offset by adding empty vector. Virus release was determined as described above, and expressed as the percentage of maximal virus release in
the absence of HA-BCA2 or the DRing BCA2 mutant. To determine the infectivity of influenza H1N1, 293T cells were infected with 1 ml of H1N1
virions produced from HA-BCA2-expressing cells. Infectivity was determined 24 hours post-infection by measuring the amount of influenza
hemagglutinin protein (HA) protein present on the cell surface. Similar to panels B and D, whole cell lysates and virions generated from transfections
with HA-BCA2 (F) and DRing BCA2 (G) were analyzed by western blot. Error bars represent standard deviation of independent experiments.
doi:10.1371/journal.ppat.1004151.g001
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Gag was determined by probing western blot membranes with an
anti-Ubiquitin (Ub) antibody. To control for the presence of the
GFP tag associated to Gag, as a potential target for BCA2-
ubiquitination, we performed ubiquitination assays in parallel for
Gag-GFP and native Gag expressed from proviral DNA. The
levels of ubiquitination in HIV-1 and SIV Gag increased in cells
expressing HA-BCA2, either for native Gag as for Gag-GFP.
However, the levels of Ub-Gag were similar to those observed in
the presence of the empty vector control in cells expressing the
ligase-dead mutant of BCA2 (DRing BCA2) (Figure 3B). Hence,
these results support that BCA2 promotes Gag ubiquitination.
We next ran computational analyses to identify lysine residues
in HIV-1 and SIV Gag susceptible to become ubiquitinated
(Tables 1 and 2). Alanine substitutions were introduced at those
positions, and the ubiquitinated status of those mutants was tested
along with wild-type Gag and a Gag-myristoyl mutant (G2A)
(Figure 3C). HIV-1 Gag was found to become ubiquitinated in the
presence of HA-BCA2, but its ubiquitination levels were almost
undetectable in cells co-transfected with the empty vector control.
Consistent with the requirement of an intact RING-finger domain
for the E3 ligase activity, almost no Ub-Gag was detected in cells
expressing DRing BCA2, and auto-ubiquitination was also lost for
this mutant. Interestingly, prevention of the addition of a myristoyl
Figure 2. The E3 ligase activity of BCA2 is required for antiviral activity. (A) Schematic representation of BCA2 with the N-terminal BCA2
Zinc-finger domain (BZF), the AKT-phosphorylation sites, and the C-terminal RING-finger domain. Key residues are indicated. (B) Virus release assays
for HIV-1 NL4-3, SIVmac239 and Mo-MLV were performed from cells expressing wild-type HA-BCA2 or the indicated BCA2 mutants, and expressed as
the percentage of maximal release, as previously described. The whole cell lysates (WCL) and the virions produced were also analyzed by western blot
to assess HA-BCA2, Gag, Nef, CA and b-actin expression. Red asterisk indicates MW of 37 KDa. (C) The tetherin-independent and tetherin-dependent
antiviral activity of BCA2 was examined in a virus release assay from parental 293T and 293T cells stably expressing tetherin. Results were also
corroborated by western blot of the whole cell lysates (WCL) and pelleted virions. Error bars represent standard deviation of independent
experiments.
doi:10.1371/journal.ppat.1004151.g002
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PLOS Pathogens | www.plospathogens.org 5 May 2014 | Volume 10 | Issue 5 | e1004151Figure 3. BCA2 induces the ubiquitination of retroviral Gag proteins. Retroviral Gag proteins were tested for BCA2-induced ubiquitination
by co-transfecting 293T cells with vectors expressing codon-optimized HIV-1 NL4-3, SIVmac239 and Mo-MLV Gag proteins along with an expression
vector coding for HA-BCA2 or empty vector. (A) Cell lysates were incubated with a polyubiquitin affinity resin and the bound fraction was eluted and
analyzed by western blot. Membranes were probed with antibodies specific for p55/p24, MLV p30 and HA. Whole cell lysates were set aside for
western blot analyses. (B) The BCA2-induced ubiquitination of Gag-GFP as well as native Gag was analyzed in side-by-side experiments. 293T cells
were co-transfected in duplicate with each Gag construct, HA-BCA2, DRing BCA2 or empty vector. Cell lysates were set aside for regular western
blotting, and the rest of the lysates were immunoprecipitated with an antibody anti-CA. Membranes were developed with an anti-Ubiquitin (Ub)
BCA2 Has Intrinsic Anti-HIV Activity
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indicating that Gag must be associated to cellular membranes in
order to be targeted by BCA2. Mutation of K27 in HIV-1 Gag did
not affect BCA2-mediated ubiquitination. However, alanine
substitutions at positions 113, 114, and 418 in HIV-1 Gag
significantly reduced the levels of Gag-associated Ubiquitin, and
combination of all alanine substitutions (K5) further decreased the
levels of Ub-Gag (Figure 3C). In accordance with the previously
mentioned enzymatic characteristics of BCA2, the auto-ubiquiti-
nation levels of HA-BCA2 were considerably lower in the presence
of HIV-1 Gag proteins susceptible to become ubiquitinated than
in the presence of HIV-1 Gag mutants that were resistant to
ubiquitination. Remarkably, the defect in HIV-1 Gag expression
was only observed when the levels of ubiquitinated Gag increased
(Figure 3B and 3C).
Similar results were obtained for SIV Gag (Figure 3D). The
ubiquitination levels of SIV Gag increased in the presence of HA-
BCA2, and almost no Ub-Gag was detected in the presence of the
DRing BCA2 mutant. Mutation of K336 in SIV Gag had
practically no effect on its Ubiquitin levels, and a significant
reduction in Ub-Gag was observed with the Gag mutant
containing an alanine substitution at position 360 and also,
although less dramatic, with the alanine mutant at position 419.
Combination of these mutations (K3) further reduced Ub-Gag
(Figure 3D), indicating that BCA2 primarily targets K360 and also
K419 in SIV Gag for ubiquitination (a schematic representation of
the positions of these lysine residues is provided in Figure 3E).
Consistent with the decreased auto-ubiquitination levels of HA-
BCA2 observed in the presence of HIV-1 Gag, HA-BCA2 was
more ubiquitinated in the absence of SIV Gag, or in the presence
of the SIV Gag K3 mutant, than in the presence of SIV Gag
proteins susceptible to become ubiquitinated (Figure 3D). Accord-
ingly, the cellular levels of SIV Gag were substantially restored for
Gag mutants resistant to BCA2-mediated ubiquitination
(Figure 3D). Therefore, the antiviral effects of BCA2 on HIV-1
and SIV Gag expression correlate with the ability of BCA2 to
promote the ubiquitination of these Gag proteins.
BCA2 physically interacts with Gag
The BCA2-induced ubiquitination of HIV-1 and SIV Gag
suggests that BCA2 physically interacts with Gag proteins to
promote their ubiquitination. To explore this, retroviral Gag
proteins were tested for a physical interaction with BCA2 by co-
immunoprecipitation assays. HIV-1, SIV and Mo-MLV Gag were
immunoprecipitated from lysates of 293T cells co-transfected with
constructs expressing HA-BCA2 and each of these retroviral Gag
proteins (Figure 4A). Immunoprecipitated proteins were separated
by SDS-PAGE, and western blot membranes were probed with a
monoclonal antibody to HA. HA-BCA2 was strongly pulled down
in the presence of Mo-MLV Gag, whereas a weaker interaction
was detected with SIV and HIV-1 Gag (Figure 4A). These results
were confirmed two additional times. To identify the region in
Gag that interacts with BCA2, new co-immunoprecipitation assays
were performed with Gag-GFP deleted mutants (Figure 4B, upper
diagrams). HA-BCA2 was pulled down in the presence of the full-
length HIV-1 Gag-GFP protein as well as MACA-GFP and MA-
GFP, but not in the presence of CA-GFP and NC-GFP, indicating
that BCA2 and HIV-1 Gag interact through the Matrix region of
Gag. These results were confirmed by performing reciprocal co-
immunoprecipitation assays, where Gag-GFP constructs contain-
ing the Matrix region of HIV-1 Gag were immunoprecipitated
with HA-BCA2 (Figure S4). In agreement with our ubiquitination
data, this interaction was significantly reduced in cells expressing
the HIV-1 Gag-G2A-GFP mutant, further confirming that Gag
must be associated to cellular membranes to be targeted by BCA2
(Figure 4C). Similar results were obtained for SIV Gag. HA-BCA2
was pulled down in the presence of the full-length SIV Gag-GFP
protein or constructs containing the Matrix region of Gag
(Figure 4D).
To identify the region in BCA2 interacting with HIV-1 and SIV
Gag, similar experiments were performed in the presence of HA-
BCA2 deleted mutants (Figure 4B, lower diagrams). In this case,
HIV-1 and SIV Gag both immunoprecipitated with the full-length
HA-BCA2 protein as well as with DRing BCA2 and a GST-BCA2
fusion protein lacking the C-terminus of BCA2 (residues 148–305:
antibody. (C) The ubiquitination of HIV-1 Gag, or HIV-1 Gag mutants, in cells expressing HA-BCA2 was also analyzed by immunoprecipitation. Cell
lysates were set aside for western blot analyses and the rest of the samples were immunoprecipitated with an anti-CA specific antibody. Membranes
were probed with an anti-Ubiquitin antibody. Similarly, the ubiquitination levels of HA-BCA2 were also determined. In this case, samples were
immunoprecipitated using an anti-HA antibody. Results were confirmed in two additional independent assays. (D) A similar approach was used to
analyze the ubiquitination levels of SIV Gag, or SIV Gag mutants, in the presence and absence of HA-BCA2. (E) Schematic representation of the
putative lysine residues susceptible to become ubiquitinated by BCA2 in HIV-1 and SIV Gag (red). IP: immunoprecipitation. IB: immunoblot. WCL:
whole cell lysate. V: empty vector.
doi:10.1371/journal.ppat.1004151.g003
Table 1. Lysine residues in HIV-1 Gag predicted to become ubiquitinated.
Peptide Position Score Threshold
RLPGGKKKYLKHI 27 2.55 0.3
EEQNKSKKKAQQAAA 113 1.85 0.3
EQNKSKKKAQQAAAD 114 2.34 0.3
PDCKTILKALGPAAT 335 2.02 0.3
GVGGPGHKARVLAEA 359 2.91 0.3
KGCWKCGKEGHQMKD 418 1.74 0.3
The complete coding sequence of HIV-1 Gag was analyzed by a Bayesian Discriminant Method algorithm (http://bdmpub.biocuckoo.org/). The selected amino acids
obtained the highest score for the prediction.
doi:10.1371/journal.ppat.1004151.t001
BCA2 Has Intrinsic Anti-HIV Activity
PLOS Pathogens | www.plospathogens.org 7 May 2014 | Volume 10 | Issue 5 | e1004151DC-GST), but not with GST, indicating that the interaction
between Gag and BCA2 takes place within the first half of the
protein (residues 1–147) (Figure 4E and 4F). These results were
confirmed in two independent assays. In order to perform a loss of
binding assay, we engineered a BCA2 deleted mutant lacking the
N-terminal Zinc-finger domain. However, the expression levels of
this construct were practically undetectable, even when fused to
GST (data not shown). Thus, we decided not to include this
mutant in our mapping studies.
BCA2 promotes the lysosomal degradation of HIV-1 and
SIV Gag
The fact that the BCA2-induced defect in Gag expression
correlates with Gag ubiquitination, suggests that BCA2 promotes
the degradation of retroviral Gag proteins. To explore this, the
antiviral effects of BCA2 were analyzed in the presence of
proteasomal and lysosomal inhibitors. 293T cells were co-
transfected with HIV-1 NL4-3 or SIVmac239 proviral DNA and
a construct coding for HA-BCA2 or empty vector. Twenty-four
hours post-transfection, the cells were washed and fresh medium
was added containing either DMSO, proteasomal inhibitor drugs
(ALLN, clasto-Lactacystin b-lactone) or drugs that impair
lysosomal function (Chloroquine, Pepstatin A, Leupeptin and/or
E64). The accumulation of virus particles in the culture
supernatant was measured by HIV-1 p24 or SIV p27 antigen-
capture ELISA 48 hours post-transfection, and expressed as the
percentage of maximal release in the absence of HA-BCA2
(Figure 5). The results obtained were confirmed in four
independent experiments. As expected, transfections with HA-
BCA2 constructs resulted in a ,3-fold reduction in the amount of
virus particles present in the culture supernatant compared to
transfections with an empty vector. The addition of proteasomal
inhibitors to cells expressing HA-BCA2 further decreased virus
release for both, HIV-1 NL4-3 and SIVmac239. Western blot
analyses of the cell lysates and pelleted virions confirmed these
observations, and revealed a substantial increase in the steady-state
levels of HA-BCA2 in the presence of proteasomal inhibitors
(Figure 5A). This is consistent with a previous report demonstrat-
ing that the auto-ubiquitination activity of BCA2 reduces its
stability, so it is rapidly degraded through the proteasome.
Therefore, in the presence of drugs that block proteasomal
degradation, the turnover of BCA2 is reduced [34]. In fact,
treatment of parental 293T cells with increasing concentrations of
ALLN led to increased levels of endogenous BCA2 and resulted in
a dose-dependent decrease in cellular levels of HIV-1 Gag and
virus release (Figure 5B). The effects of ALLN on Gag expression
and virus release were reversed in cells depleted from BCA2
(Figure S5A and S5B), further supporting that this effect was
BCA2-specific. Therefore, the higher restriction in virus release
observed in the presence of these proteasomal inhibitors reflects an
increase in BCA2 steady-state levels, and thereby in antiviral
activity, and indicates that the BCA2-induced reduction of Gag
does not involve proteasomal degradation.
We next examined if BCA2 induces the lysosomal degradation
of Gag by adding Chloroquine, a lysosomotropic drug, to the
culture medium. The antiviral effects of BCA2 on virus release
were impaired in the presence of this drug, since there was .2-fold
rescue in particle release (Figure 5C). This was confirmed by
western blot. In this case, no increase in the cellular levels of HA-
BCA2 was observed, and the levels of cellular Gag and virion-
associated capsid were significantly restored (Figure 5C). To
confirm these results, additional assays were performed in the
presence of drugs that specifically inhibit lysosomal proteases. The
addition of Pepstatin A (inhibitor of aspartic proteases) alone or in
combination with Leupeptin (serine and cysteine proteases
inhibitor) and E64 (cysteine protease inhibitor) to cells expressing
HA-BCA2 also resulted in a ,2-fold increase in virus release
compared to the amount of virus particles released from cells
expressing HA-BCA2 and treated with DMSO (Figure 5D). These
observations were corroborated by western blot analyses, showing
a substantial rescue in Gag expression in cells treated with
lysosomal inhibitors, which also results in a rescue in the levels of
virion-associated capsid (Figure 5D, bottom panel). To test if these
drugs would intrinsically increase virus release, similar assays were
performed side-by-side in vector-transfected and HA-BCA2-
expressing cells. The addition of inhibitors of lysosomal proteases
only resulted in increased virus release under conditions of ectopic
expression of BCA2 (Figure S5C). The fact that the inhibitory
effects of BCA2 on virus release were not fully reverted in the
presence of these drugs may suggest that additional routes or
factors contribute to the antiviral activity of BCA2, but may also
reflect an additional role for components of the endo-lysosomal/
autophagy pathway in virus assembly and release
[35,36,37,38,39]. To further explore the role of the endo-
lysosomal pathway in the mechanism of BCA2 restriction, we
examined the effects of a dominant-negative mutant of Rab7A
(Rab7 N125I) –a BCA2-interacting GTPase associated with both
the endosome and lysosome– on the activity of endogenous and
ectopically expressed BCA2 (Figure S5D). Expression of Rab7
N125I increased virus release from parental 293T cells (solid bars)
as well as from HA-BCA2 expressing cells (bars with a pattern),
and this increase in virus release correlates with a substantial
rescue in Gag and CA levels (Figure S5D, bottom panel).
Therefore, these results support that BCA2 induces the lysosomal
degradation of retroviral Gag proteins, which is in agreement with
the fact that BCA2 interacts with Rab7 [27,28].
The targeted depletion of BCA2 results in increased virus
release and replication, even in cells not expressing
tetherin
Several cell types express basal levels of BCA2, including 293T
cells. Therefore, we wanted to investigate if endogenous BCA2 has
Table 2. Lysine residues in SIV Gag predicted to become ubiquitinated.
Peptide Position Score Threshold
PDCKLVLKGLGVNPT 336 2.51 0.3
GVGGPGQKARLMAEA 360 2.13 0.3
QGCWKCGKMDHVMAK 419 1.78 0.3
The full coding sequence of SIV Gag was analyzed by a Bayesian Discriminant Method algorithm (http://bdmpub.biocuckoo.org/). The selected amino acids obtained
the highest score for this prediction.
doi:10.1371/journal.ppat.1004151.t002
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PLOS Pathogens | www.plospathogens.org 8 May 2014 | Volume 10 | Issue 5 | e1004151Figure 4. The N-terminus of BCA2 interacts with the Matrix region of Gag. (A) To investigate if retroviral Gag proteins interact with BCA2,
293T cells were co-transfected with HIV-1, SIV and Mo-MLV Gag constructs and either empty vector or a vector encoding HA-BCA2. Cell lysates were
immunoprecipitated with a CA-specific antibody and membranes were probed with an anti-HA antibody. Results obtained from these assays were
corroborated independently twice. (B) Schematic representation of the Gag and HA-BCA2 deleted constructs used. Similar to panel A, HIV (C) and SIV
(D) Gag deleted mutants were tested for an interaction with HA-BCA2 by co-immunoprecipitation. Likewise, HA-BCA2 deleted mutants were tested
for an interaction with HIV (E) and SIV (F) Gag proteins by co-immunoprecipitation. In this case, lysates were immunoprecipitated with an anti-HA
antibody and western blot membranes were probed with a GFP-specific antibody. Whole cell lysates (WCL) were set aside to check the input levels of
these proteins and b-actin. IP: immunoprecipitation. V: empty vector.
doi:10.1371/journal.ppat.1004151.g004
BCA2 Has Intrinsic Anti-HIV Activity
PLOS Pathogens | www.plospathogens.org 9 May 2014 | Volume 10 | Issue 5 | e1004151Figure 5. BCA2 promotes the lysosomal degradation of HIV-1 and SIV Gag. To determine if BCA2 promotes the proteasomal or lysosomal
degradation of retroviral Gag proteins, virus release assays for HIV-1 and SIV were performed in the presence of proteasomal inhibitors (A-B) and
lysosomal inhibitors (C-D). Virus release was measured by HIV-1 p24 or SIV p27 antigen-capture ELISA and expressed as the percentage of maximal
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cells, which do not express endogenous tetherin [15], were
transfected with lentiviral-based vectors coding for BCA2-specific
shRNAs (sh-BCA2-1, sh-BCA2-3 and sh-BCA2-4) or scrambled
shRNA. After two rounds of shRNA transfections, the cells were
transfected with HIV-1 NL4-3 or SIVmac239 proviral DNA. Virus
release was measured 48 hours post-transfection as previously
described, and expressed as the percentage of maximal release of
three independent assays. The knock down of BCA2 was
confirmed by western blot using a BCA2-specific antibody, and
comparing the expression of endogenous BCA2 to b-actin. The
targeted depletion of BCA2 in 293T cells resulted in a 3 to 5-fold
increase in virus release compared to scrambled shRNA-treated
cells (Figure 6A). This was corroborated by western blot analyses
showing an increase in Gag expression in cells depleted from
BCA2, without affecting the expression levels of other viral
proteins. Similar results were obtained in HOS cells, where the
best knockdown of BCA2 afforded ,4-fold increase in virus
release (Figure 6B).
To investigate the relevance of endogenous BCA2 for HIV-1
and SIV replication in target cells, human Jurkat CD4
+ T cells and
221T cells, a Herpesvirus saimiri-immortilized rhesus macaque CD4
+
T cell line [40], were transduced with scrambled shRNA or
BCA2-specific shRNAs. The knockdown of BCA2 was assessed by
western blot, as described above. Virus replication for HIV-1
NL4-3 increased by ,10-fold at day 8 post-infection in cells
transduced with sh-BCA2-3, which afforded the best effect on
depleting BCA2 in Jurkat cells. In cells transduced with sh-BCA2-
4, which only had a minor reduction in the endogenous levels of
BCA2, there was only a 2.5-fold increase in virus replication. An
intermediate phenotype (,5-fold enhancement) was observed in
cells transduced with sh-BCA2-1, which afforded intermediate
effects on the knockdown of BCA2 (Figure 6C). Similar results
were obtained for SIV in 221T cells, where virus replication was
15-fold higher in cells treated with sh-BCA2-3, which afforded the
best knockdown of endogenous BCA2, compared to cells treated
with scrambled shRNA (Figure 6D). Therefore, these observations
indicate that endogenous BCA2 has antiviral activity.
BCA2 induces changes in the subcellular distribution of
Gag
Changes in the subcellular distribution of HIV-1 and SIV Gag
were examined in HA-BCA2-expressing and parental cells by
confocal microscopy. 293T cells were transfected with constructs
coding for either HIV-1 Gag-GFP, SIV Gag-GFP, or proviral
DNA for HIV-1 and SIV, along with a vector encoding HA-BCA2
or empty vector. Cells were stained for GFP or CA (green), HA-
BCA2 (red) and the nuclei (blue). In HA-BCA2 expressing cells,
BCA2 was found to localize primarily in the cytoplasm, but also in
the nucleus, as previously reported [32] (Figure 7A). In parental
cells, native HIV-1 Gag, HIV-1 Gag-GFP, native SIV Gag and
SIV Gag-GFP localized mainly at the plasma membrane and also
at membrane-proximal locations (Figure 7B). In cells expressing
both, HA-BCA2 and Gag-GFP, Gag was found within the
cytoplasm, at punctuated locations (Figure 7C and 7D, left panels).
The effect of HA-BCA2 on the redistribution of Gag was also
observed in native Gag (Figure 7C and 7D, right panels).
Consistent with our data showing that myristoylation of Matrix
is required for BCA2 antiviral activity, the BCA2-induced changes
in the redistribution of Gag disappeared in cells expressing the
HIV-1 Gag-G2A-GFP mutant, since HIV-1 Gag-G2A-GFP was
found evenly distributed in the cytoplasm (Figure 8A, bottom
panels), displaying the same localization as in parental cells
(Figure 8A, top panels). To reveal the intracellular localization of
native Gag in HA-BCA2-expressing cells, 293T cells were stained
for HIV-1 p24 (green), HA-BCA2 (blue) and specific intracellular
markers (red), and the localization of Gag relative to these cellular
markers was analyzed. Consistent with a role for BCA2 in routing
Gag for lysosomal degradation, Gag co-localized with endo-
lysosomal markers (CD63 and LAMP1) (Figure 8B and 8C), but
not with markers of the trans-Golgi network (Figure S6). Similar
results were obtained for SIV Gag (data not shown). Therefore,
BCA2 induces drastic changes in the subcellular localization of
HIV-1 and SIV Gag, which are primarily found at punctuated
locations in the cytoplasm, co-localizing with endo-lysosomal
markers.
Discussion
Mammalian cells express a number of proteins that block HIV
replication. These include APOBEC3 proteins, TRIM5 members,
Mx2/MxB, SAMHD1 and tetherin/BST2 [5,6,8,9,10,11,14,15,
16,17,18,19,41]. Tetherin is an interferon-inducible transmem-
brane protein that traps nascent virions to the plasma membrane,
impairing virus release and spread. A recent study identified
BCA2, a RING-finger E3 ubiquitin ligase, as a co-factor in the
restriction imposed by tetherin on HIV-1 [27]. BCA2 was shown
to interact with sequences in the cytoplasmic domain of tetherin to
promote the internalization and lysosomal degradation of tethered
virions. However, its E3 ligase activity was dispensable for virus
restriction. Ectopic expression of BCA2 in tetherin-deficient cells
(HOS) showed no effects on HIV release. Therefore, it was
concluded that BCA2 lacks antiviral activity in the absence of
tetherin. Here we show for the first time that BCA2 possesses
tetherin-independent antiviral activity that leads to the ubiquitina-
tion and lysosomal degradation of HIV-1 and other retroviral Gag
proteins, thereby, impairing virus assembly and release.
Increasing concentrations of BCA2 in 293T cells, which do not
express endogenous tetherin [15], resulted in a dose-dependent
decrease in the amount of HIV-1 virus particles released into the
cell culture supernatant, suggesting that BCA2 has antiviral
activity even in the absence of tetherin. Western blot analyses
revealed that this defect in virus release corresponds to a reduction
in the expression levels of Gag, with no effects on other viral
proteins. Therefore, the antiviral activity of BCA2 seems to
specifically target the Gag polyprotein. Similar results were
obtained for SIV and Mo-MLV, but no antiviral activity was
observed against influenza virus H1N1 PR8, indicating that BCA2
possesses antiviral activity against several retroviruses, but its
inhibitory effects are not of broad range.
The discrepancy of these results with those from Miyakawa et
al. [27] may be due to the use of different cell lines (293T instead
of HOS cells). To test this, we performed additional assays in HOS
cells. However, we had similar results to those obtained in 293T
cells (data not shown). This is consistent with our shRNAs assays,
which demonstrate that endogenous BCA2 in HOS cells has
antiviral activity. Since there are many commercially available
HOS cells, we hypothesize that the ones used by Miyakawa might
be deficient in factors required for BCA2 antiviral activity.
Nevertheless, unlike Miyakawa’s observations, our data clearly
shows that, besides a synergistic effect on virus restriction in the
virus release in the absence of HA-BCA2. The cell lysates (WCL) and virions derived from these transfections were analyzed by western blot. Clasto:
clasto-Lactacystin b-lactone. Chlor: chloroquine. Error bars represent standard deviation of independent experiments.
doi:10.1371/journal.ppat.1004151.g005
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PLOS Pathogens | www.plospathogens.org 11 May 2014 | Volume 10 | Issue 5 | e1004151Figure 6. The targeted depletion of endogenous BCA2 results in increased virus release and replication. Endogenous BCA2 was
depleted by shRNA from 293T cells (A) and HOS cells (B) by transient transfection. Cells were subsequently transfected with HIV-1 NL4-3 or SIVmac239
proviral DNA, and virus release was measured 48 hours later. Depletion of endogenous BCA2 was also achieved in CD4
+ T cells by transduction. Next,
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independent antiviral factor that impairs virus release.
Unlike the tetherin-dependent antiviral activity of BCA2 [27],
the E3 ligase activity is required for tetherin-independent
restriction, since overexpression of BCA2 mutants with impaired
ligase activity did not interfere with virus release or Gag
expression. Consistent with these results, ubiquitination assays
revealed that HIV-1 and SIV Gag become ubiquitinated in the
presence of BCA2. In accordance with a previously reported
intrinsic preference for substrate ubiquitination versus auto-
ubiquitination [33], the auto-ubiquitination activity of BCA2
was dramatically reduced in the presence of Gag proteins
susceptible to BCA2-mediated ubiquitination. The introduction
of alanine substitutions at lysine residues in Gag predicted to
become ubiquitinated (particularly at K113, K114, and K418 in
HIV-1 Gag; K360 and K419 in SIV Gag) impaired the BCA2-
induced ubiquitination of Gag, a fact that was more evident when
those alanine substitutions were combined. The fact that BCA2
promotes the ubiquitination of retroviral Gag proteins raised the
possibility that BCA2 and Gag physically interact. Co-immuno-
precipitation assays revealed a physical interaction between these
two proteins, and we further mapped this association to the Matrix
region in Gag and the first half portion of BCA2.
Our ubiquitination assays also showed that the BCA2-induced
ubiquitination of Gag directly correlates with a reduction in Gag
levels, suggesting that BCA2 may promote the ubiquitination and
degradation of retroviral Gag proteins. Assays with proteasomal
inhibitors showed further inhibition in virus release in cells
expressing BCA2. Western blot analyses revealed a substantial
increase in the steady-state levels of BCA2 in the presence of these
drugs, which is in agreement with previous reports [34]. Indeed,
treatment of parental 293T cells with proteasomal inhibitors led to
increased BCA2 levels and a corresponding reduction in Gag and
virus release. Therefore, not only this assay proves the existence of
BCA2-specific antiviral activity, but also that the BCA2-dependent
defect in Gag levels does not require the proteasome. On the other
hand, assays with lysosomal inhibitors showed a significant rescue
in virus release in cells expressing BCA2. However, virus release
was not restored to the levels achieved in cells transfected with the
empty vector control, suggesting that BCA2 promotes, at least in
part, the lysosomal degradation of Gag, but other pathways may
also be involved in the mechanism of restriction. The BCA2-
induced lysosomal degradation of Gag is consistent with a
previously reported interaction between BCA2 and Rab7
[27,28], a GTPase associated with lysosomal biogenesis. Indeed,
assays with a dominant-negative mutant of Rab7 impaired BCA2
function and led to increased Gag levels, and therefore, a
substantial rescue in virus release. Moreover, BCA2 has recently
been shown to route EGFR for endosomal sorting [42,43], further
corroborating the connection of BCA2 with the endo-lysosomal
pathway.
BCA2 localizes uniformly in the cytoplasm and nucleus [32],
whereas HIV-1 Gag is primarily found at the plasma membrane
or at membrane-proximal locations [44,45]. The effects of BCA2
on the subcellular distribution of HIV-1 and SIV Gag were
studied by confocal microscopy. Whereas HIV-1 and SIV Gag
localized mainly at the plasma membrane in parental 293T cells,
the intracellular distribution of these Gag proteins was reorganized
in cells expressing HA-BCA2, since Gag was found at punctuated
locations in the cytoplasm. Strikingly, mutation of the Matrix
myristoylation site, which prevented the localization of Gag at the
plasma membrane [45], also prevented the intracellular re-
distribution of Gag observed in cells expressing HA-BCA2. These
results are consistent with our data showing that Gag must be
associated to the plasma membrane in order to be susceptible to
BCA2. An analysis of the subcellular distribution of Gag in HA-
BCA2-expressing cells revealed that Gag co-localized with endo-
lysosomal markers, further supporting a role for BCA2 in targeting
Gag for lysosomal degradation.
Although BCA2 was initially found to be overexpressed in .
50% of invasive breast cancers [32], it is endogenously expressed
in a variety of tissues (source Human Atlas). To explore if
endogenous BCA2 possesses antiviral activity, BCA2 was specif-
ically depleted from 293T, HOS, Jurkat and 221T cells by
shRNA. The targeted depletion of BCA2 in 293T and HOS cells,
which do not express endogenous tetherin [15], resulted in a 3 to
5-fold increase in virus release, corroborating that BCA2 has
antiviral activity even in the absence of tetherin. The depletion of
BCA2 in T cell lines led to up to 15-fold increase in virus
replication compared to shRNA-scrambled-treated cells. Since
BCA2 impairs virus assembly and release, an increase in virus
production will also be reflected by an increase in virus replication,
since more virions are being generated, which can therefore infect
more target cells.
In summary, here we show that BCA2 functions mainly as a
tetherin-independent factor that leads to the ubiquitination of
HIV-1 and other retroviral Gag proteins and, consequently, their
lysosomal degradation. Therefore, BCA2 poses a significant
barrier in virus assembly and release. Further work will determine
the range of viruses susceptible to this E3 ligase, if viral pathogens
have evolved countermeasures to BCA2, and explore if BCA2 is
connected to immune signaling pathways.
Materials and Methods
Plasmid DNA constructs
(a) BST2 expression constructs. Human BST2 (hBST2) and
rhesus macaque BST2 allele rBST2.1 were cloned as previously
described [22,29].
(b) BCA2 expression constructs. Human BCA2 was cloned
from cDNA of PBMCs into the pcDNA5 expression vector using
the unique restriction sites AflII and BamHI. HA-tagged versions
of BCA2, as well as BCA2 deleted mutants, were originated by
PCR manipulation and cloned into pcDNA5.
(c) HIV-1, SIV and MLV proviral clones. Full-length HIV-
1 NL4-3 proviral DNA (pNL4-3) was obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr.
Malcolm Martin, and HIV-1 NL4-3 Dvpu was generated by site-
directed mutagenesis as previously described [22]. Full-length
clones for wild-type SIV and SIV Dnef were constructed from the
following clones based on SIVmac239; p239SpSp5’, pSP72-239-3’
and pSP72-239-3’Dnef [46,47]. Full-length Mo-MLV proviral
DNA (pNCS) was obtained from Addgene, Cambridge, MA.
(d) Gag expression constructs. HIV-1 Gag (pGag-EGFP)
was obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH from Dr. Marilyn Res. A
virus replication was assessed for HIV-1 in Jurkat cells (C) and for SIV in 221 T cells (D) by HIV-1 p24 and SIV p27 antigen-capture ELISA, respectively, at
selected time points. The depletion of endogenous BCA2 was confirmed by western blot for each of these cell lines, by comparing the levels of
endogenous BCA2 in the whole cell lysate (WCL) to those of b-actin. Error bars represent standard deviation of independent experiments.
doi:10.1371/journal.ppat.1004151.g006
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using the unique restriction sites SacII and BamHI to obtain the
fusion protein SIV Gag-EGFP. Mutations in HIV-1 and SIV Gag
were introduced by Quickchange site-directed mutagenesis
according to the manufacturer guidelines (Stratagene, La Jolla,
CA). Gag deleted mutants were originated by overlapping PCR
and cloned into pEGFP.
(e) Dominant-negative mutants. A Rab7A-RFP construct
was kindly provided by Dr. I-Chue Huang, University of
Riverside, CA. The dominant negative mutant Rab7 N125I was
Figure 7. BCA2 leads to the accumulation of Gag proteins within intracellular compartments. The effects of BCA2 on Gag distribution
were investigated by confocal microscopy. 293T cells were co-transfected with constructs coding for HA-BCA2 and HIV-1 Gag-GFP, SIV Gag-GFP or
empty vector. Similar assays were performed in the presence of HIV-1 NL4-3 and SIVmac239 proviral DNA. Cells were stained for HA-BCA2 (red), Gag-
GFP or Capsid (p24 or p27) (green) and the nuclei (blue). (A) Cellular distribution of HA-BCA2 in Gag-deficient cells. (B) Cellular distribution of HIV-1
Gag-GFP, SIV Gag-GFP (left panels) and HIV-1 p24 or SIV p27 (right panels) in HA-BCA2-deficient cells. (C) Cellular distribution of HIV-1 Gag-GFP and
HIV-1 p24 in cells expressing HA-BCA2. (D) Cellular distribution of SIV Gag-GFP and SIV p27 in HA-BCA2-expressing cells. The white scale bar
corresponds to 10 mm for images with more than one cell, and 7.5 mm for images with single cells.
doi:10.1371/journal.ppat.1004151.g007
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above (Stratagene, La Jolla, CA).
Virus release assays
293T cells (5610
4) were co-transfected with wild-type or deleted
mutants of HIV-1 NL4-3, SIVmac239 or Mo-MLV proviral DNA
(100 ng) and either empty vectors, pcDNA3-hBST2, pcDNA3-
rBST2, pcDNA5-HA-BCA2 or pcDNA5-HA-BCA2 mutants
(100 ng). Differences in the amount of plasmid DNA in each
transfection were offset by the addition of empty vector (100 ng),
either pcDNA3 or pcDNA5. All transfections were performed in
duplicate in 24-well plates using GenJet Lipid Transfection
Reagents (SignaGen Laboratories, Gaithersburg, MD), and results
were confirmed in at least three independent assays. Forty-eight
hours post-transfection, the amount of virions released into the cell
culture supernatant was measured by HIV-1 p24, SIV p27
antigen-capture ELISA (Advanced Bioscience Laboratories, Inc.,
Kensington, MD) or MuLV p30 core ELISA (Cell Biolabs, San
Diego, CA), and virus release was expressed as the percentage of
maximal virus release in the absence of BCA2 or tetherin, as
previously described [22,25,29].
A similar approach was performed for assays with proteasomal
and lysosomal inhibitors. Twenty-four hours post-transfection, the
cell medium was changed and fresh medium was added containing
either DMSO, ALLN (25 mM), clasto-Lactacystin b-lactone
(20 mM), Chloroquine (0.1 nM), Leupeptin (20 mM), E64
(10 mM) or Pepstastin (20 mM). The accumulation of virus
particles in the cell culture supernatant was assessed forty-eight
hours post-transfection by HIV-1 p24 or SIV p27 antigen-capture
ELISA, and virus release was expressed as the percentage of
maximal release in the absence of HA-BCA2.
Influenza infectivity
293T cells (3610
5) were seeded in 6-well plates. Twenty-four
hours later, cells were transfected with increasing concentrations
(0–1000 ng) of pcDNA5-HA-BCA2. Differences in DNA concen-
trations were offset by the addition of empty vector (pcDNA5).
Twenty-four hours later, cells were infected with influenza H1N1
PR8 (kindly provided by Dr. Gack, Harvard Medical School) at a
multiplicity of infection (MOI) of 3. Two days post-infection, the
cell culture supernatant containing newly formed H1N1 virions
was collected, and used for a second infectivity assay (1 ml of
culture supernatant) on parental 293T cells, which were seeded the
day before at 3x10
5 cells per well in 6-well plates. Twenty-four
hours after this second infection, cells were carefully detached
using cell dissociation buffer (Sigma-Aldrich, St Louis, MO) and
stained for the surface expression of the influenza hemagglutinin
protein (HA). For this, a mouse monoclonal antibody anti-HA was
used (Takara Bio, Japan) at a dilution of 1:100, followed by
washing steps with PBS and incubation with a secondary goat anti-
mouse IgG PE-conjugated antibody (Sigma-Aldrich, St Louis,
MO). After two washing steps with PBS, cells were fixed with 2%
paraformaldehyde and analyzed by flow cytometry. Data were
collected using a FACSCalibur flow cytometer (Becton Dickenson)
and analyzed using FlowJo 8.8.7 software (TreesStar). Results
were corroborated in two additional independent assays.
Western blots
The whole cell lysates and the culture supernatants of
transfected cells were analyzed by western blot, as previously
described [22,25,29]. Forty-eight hours post-transfection, cell
lysates were prepared by harvesting in 2x SDS sample buffer
(Sigma-Aldrich, St Louis, MO). Virions were recovered from the
cell culture supernatant by centrifugation at 14,000 rpm for
2 hours at 4uC, and resuspended in 2x SDS sample buffer.
Samples were boiled for 5 minutes, and separated by electropho-
resis on 8–12% SDS-polyacrylamide gels and transferred to
polyvinylidine fluoride (PVDF) membranes using a Trans-Blot SD
transfer cell (BioRad, Hercules, CA). The membranes were then
blocked with 5% non-fat dry-milk in PBS containing 0.05%
Tween-20 for 1 hour, and probed overnight at 4uC with one of the
following primary antibodies. Endogenous BCA2 was detected
with a rabbit polyclonal antibody against ZNF364 (abcam,
Cambridge, MA) at a dilution of 1:500. Tetherin/BST2 was
detected with a mouse polyclonal antibody (abcam, Cambridge,
MA) at a dilution of 1:500. The HIV-1 and SIV Gag proteins p55
and p24 or p27, respectively, were detected with the mouse
monoclonal antibody 183-H12-5C (AIDS Research and Refer-
ence Reagent Program, Division of AIDS, NIAID, NIH) at a
dilution of 1:1000. HIV-1 Nef protein was detected with rabbit
antiserum (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) at 1:500 dilution. HIV-1 Vpu was
detected with rabbit antiserum (AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH) at 1:500
dilution. SIV Nef was detected using the mouse monoclonal
antibody 17.2 (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) at a dilution of 1:1000. SIV Env
was detected with the mouse monoclonal antibody KK41 (AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH) at a dilution of 1:1000. Endogenous b-actin was
detected with the mouse monoclonal antibody C4 (Chemicon,
Billerica, MA) at a dilution of 1:1000. HA-tagged BCA2 and other
BCA2 mutants were detected with the HA-specific mouse
monoclonal antibody HA.11 (Covance, Princeton, NJ) at a
dilution of 1:1000. The GFP fusion proteins HIV-1 Gag-GFP
and SIV Gag-GFP were detected using either an anti-GFP mouse
monoclonal antibody (Sigma-Aldrich, St Louis, MO) at a dilution
of 1:1000, a rabbit monoclonal antibody (abcam, Cambridge, MA)
at a dilution of 1:1000 or the mouse monoclonal anti-Gag (AIDS
Research and Reference Reagent Program). In this case, a
difference in the pattern of HIV-1 Gag-GFP and SIV Gag-GFP
proteins is observed, since this antibody has more affinity for HIV-
1 Gag and therefore, the higher molecular weight bands for SIV
Gag are difficult to detect. After rinsing the PVDF membranes
three times for 15 minutes in PBS 0.05% Tween-20, the blots were
probed with an HRP-conjugated goat anti-mouse secondary
antibody (Pierce, Rockford, IL) or goat anti-rabbit secondary
antibody (abcam, Cambridge, MA) at a dilution of 1:2000 for 1
hour at room temperature. The blots were then rinsed three more
times in PBS 0.05% Tween-20, treated with SuperSignal West
Femto Maximum Sensitivity substrate (Pierce, Rockford, IL), and
imaged using a Fujifilm Image Reader LAS 3000 (Fujifilm Photo
Film Co., Japan).
Figure 8. BCA2 re-distributes HIV-1 Gag, but not HIV-1 Gag G2A, to endo-lysosomal compartments. (A) Distribution of the HIV-1 Gag-
G2A-GFP mutant in HA-BCA2
2 (top panel) and HA-BCA2
+ (bottom panels) cells. (B-C) The intracellular localization of native HIV-1 Gag in the presence
of HA-BCA2 was determined by staining cells for p24 (green), HA-BCA2 (blue) and either CD63, or LAMP1 (red). The white scale bar corresponds to
10 mm for images with more than one cell, and 7.5 mm for images with single cells.
doi:10.1371/journal.ppat.1004151.g008
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293T cells (6610
5 cells) were seeded in duplicate in 6-well
plates. Twenty-four hours later, cells were co-transfected with
constructs expressing wild-type and mutant forms HIV-1 Gag-
GFP, SIV Gag-GFP (2 mg) along with wild-type or mutants
constructs for HA-BCA2 or empty vector (pCDNA5) (2 mg).
Similar assays were performed in the context of Gag proteins
expressed from proviral DNA (HIV-1 NL4-3 and SIVmac239).
Twenty-four hours later, cells were lysed with 400 ml of IP Lysis
buffer (Thermo Scientific, Rockford, IL) and incubated on ice for
30 minutes. Lysates were transferred to 1.5 ml tubes and insoluble
cell debris was removed by centrifugation at 8,000 x g. Cell lysate
(100 ml) was set aside to confirm HA-BCA2 and Gag expression by
western blot analysis, and the rest of the sample (300 ml) was used
for immunoprecipitation. Samples for immunoprecipitation were
incubated on a rotating platform for 1 hour at 4uC with 1 mg of the
anti-HA mouse monoclonal antibody (Covance, Princeton, NJ),
anti-GFP rabbit monoclonal antibody (abcam, Cambridge, MA)
or mouse monoclonal antibody 183-H12-5C (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH).
Magnetic protein A sepharose beads (25 ml) (New England
Biolabs, Ipswich, MA) were then added, and the incubation was
continued overnight at 4uC. The beads were washed five times in
IP Lysis buffer (500 ml) and boiled in 2x SDS sample buffer.
Denatured proteins were separated on 8–12% SDS-polyacryl-
amide gels and transferred to PVDF membranes. The blots were
probed with a mouse monoclonal antibody specific for Ubiquitin
(Invitrogen, Grand Island, NY), a mouse monoclonal antibody to
detect HA (Covance, Princeton, NJ), the mouse monoclonal
antibody 183-H12-5C to detect Gag (AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH),
or a rabbit monoclonal to detect GFP (abcam, Cambridge, MA) at
a dilution of 1:1000. Membranes were next probed with an HRP-
conjugated goat anti-mouse antibody (Pierce, Rockford, IL), or
goat anti-rabbit secondary antibody (abcam, Cambridge, MA) at a
dilution of 1:2000, developed in SuperSignal West Femto
Maximum Sensitivity substrate and imaged using a Fujifilm Image
Reader LAS 3000, as described above.
shRNA-knockdown of endogenous BCA2
shRNA constructs to specifically deplete endogenous BCA2, as
well as scrambled shRNA, were provided in lentiviral vectors
(pLKO.1) through the Thermo Scientific TRC consortium (Broad
Institute,MIT andHarvard).Eachconstructwasdesignedtocontain
a hairpin consisting on a 21 base paired stem (sense and antisense
strands), separated by a 6 base loop. The following BCA2-specific
shRNAs were used for our depletion studies: TRCN0000004391
(referred hereafter as sh-BCA2-1), TRCN0000004392 (referred
hereafter as sh-BCA2-2), TRCN0000004393 (referred hereafter as
sh-BCA2-3), TRCN0000004394 (referred hereafter as sh-BCA2-4)
andTRCN0000010871(referredhereafterassh-BCA2-5).Thebest
knockdowns were achieved with constructs sh-BCA2-1, sh-BCA2-3
and sh-BCA2-4 (scores of 4.95, 15 and 10.8, respectively). The
targeted depletion of BCA2 was afforded by transient transfection
on 293T and HOS cells, according to the manufacturer instructions
(Thermo Scientific, Lafayette, CO). For replication assays in Jurkat
and 221T cells, VSV-G pseudotyped lentiviral particles were
produced to transduce each shRNA construct. The particles were
generated by transient transfection on 293T cells using psPAX2
packaging plasmid and pMD2.G envelope expressing plasmid
according to the manufacturer’s instructions (Thermo Scientific,
Lafayette, CO). Efficient knockdown of BCA2 was assessed by
western blotting after the second round of transduction from 10
6
cells, and compared to the expression of b-actin.
Virus replication in BCA2-depleted cells
Human Jurkat CD4
+ T cells and rhesus macaque 221T cells
[40], were transduced with VSV-G pseudotyped lentiviral particles
carrying scrambled shRNA or BCA2-specific shRNAs four days
prior to HIV-1 or SIV infection. After 3 hours of incubation at
37uC, cells were washed and resuspended in 5 ml of R10 or R20 +
IL-2 (100 U) medium, respectively. Forty-eight hours later, the
cells were subjected to a second round of lentiviral transduction.
Two days later, we proceeded with the infectivity assays. First, 10
6
cells were set aside for knockdown verification by western blot. 10
6
Jurkat T cells or 221 T cells were infected with 20 ng of p24 HIV-
1 NL4-3 or 20 ng of p27 of SIVmac239, respectively, and
incubated for 3 hours at 37uC. Next, cells were washed three
times and resuspended in 5 ml of R10 or R20 + IL-2. Virus
replication was monitored at selected time points by p24/p27
antigen-capture ELISA of the culture supernatant.
Confocal microscopy
293T cells (2610
4 cells in a 8-well slide) were transfected with
pcDNA5-HA-BCA2 and either pHIVGag-EGFP, pSIVGag-
EGFP expression constructs, HIV-1 NL4-3 or SIVmac239 proviral
DNA. Twenty-four hours later, cells were washed and fixed for
10 minutes in acetone/methanol and blocked for 20–60 minutes
with 100 mM glycine diluted in 10% normal goat serum in PBS
with 0.2% fish skin gelatin, 0.1% Triton x100 and 0.02% sodium
azide (10% NGS-PBS-FSG-Tx100-NaN3). The cells were then
washed three times in 10% NGS-PBS-FSG-Tx100-NaN3, and
stained. Gag expression was tracked by GFP fluorescence. The
mouse monoclonal antibody to HA (IgG1; Covance, Princeton,
NJ) was used at a dilution of 1:250 to stain for HA-BCA2. The
cells were subsequently stained with an Alexa-568-conjugated goat
anti-mouse secondary antibody specific for IgG1 (Invitrogen,
Grand Island, NY) (1:1000), and with TO-PRO3 (Invitrogen)
(1:5000) to visualize cell nuclei. In the case of transfections with
proviral DNA, Gag expression was tracked by staining for CA
(p24 or p27) with the mouse monoclonal antibody 183-H12-5C
(IgG1; AIDS Research and Reference Reagent Program). A mouse
monoclonal antibody to HA (IgG2a) was used to stain HA-BCA2
(Santa Cruz Biotechnologies, Santa Cruz, CA). Next, a secondary
Alexa-488-conjugated goat anti-mouse IgG1 and an Alexa-633-
conjugated goat anti-mouse IgG2a were used to detect Gag and
HA-BCA2, respectively. To stain intracellular compartments,
rabbit polyclonal antibodies specific for TGN46 (Sigma-Aldrich,
St Louis, MO), CD63 (Santa Cruz Biotechnology, Santa Cruz,
CA) and LAMP-1 (abcam, Cambridge, MA) were used at a
dilution of 1:50. Next, an Alexa-568 goat anti-rabbit (Invitrogen,
Grand Island, NY) was used to detect these cellular markers. After
staining, the slides were washed and mounted on with antique-
nching mounting-medium (Vector Laboratories, Inc.). Images
were acquired using a Leica TCS SP5 II confocal microscope.
Supporting Information
Figure S1 The BCA2-related defect in Gag expression is
BCA2-specific. 293T cells were co-transfected with HIV-1 NL4-3
(A) or SIVmac239 (B) proviral DNA and constructs coding for CD8-
STOP, HA-BCA2 or Dyn2-GFP. Virus release was measured
48 hours post-transfection as previously described. (C) The cell lysates
of these transfected cells were analyzed by western blot for Gag and b-
actin expression. Error bars represent standard deviation of
independent experiments. (D) Titration curve of HA-BCA2. Mem-
branes were probed with a rabbit polyclonal antibody against BCA2
to control for any effects of protein overexpression on Gag levels.
(TIF)
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the amount of infectious particles. (A) The infectivity of
HIV-1 and SIV virions generated by transient transfection from
parental 293T cells or HA-BCA2-expressing 293T cells was
evaluated on GHOST X4/R5 cells by determining the GFP
+
infected cells, and calculating the relative infectivity. (B) Cell
lysates (WCL) and virions present in the culture supernatant of
parental and HA-BCA2-expressing 293T cells were analyzed by
western blot. Error bars represent standard deviation of indepen-
dent experiments.
(TIF)
Figure S3 BCA2 interferes with Mo-MLV particle re-
lease. (A) 293T cells were co-transfected with Mo-MLV proviral
DNA and expression vectors coding for human tetherin (hBST2),
HA-BCA2 or the ligase-dead BCA2 mutant (DRing BCA2). Virus
release was measured 48 hours post-transfection by MuLV p30
ELISA, and expressed as the maximal release in the absence of
tetherin or HA-BCA2. (B) Cell lysates (WCL) and virions were
analyzed by western blot for HA-BCA2, DRing BCA2 and
tetherin expression, as well as Gag and p30. Error bars represent
standard deviation of independent transfections.
(TIF)
Figure S4 BCA2 binds to the Matrix region of HIV-1
Gag. 293T cells were co-transfected with constructs coding for
HA-BCA2, HIV-1 Gag-GFP or deleted forms of HIV-1 Gag (see
Figure 4B). Twenty-four hours later, cell lysates were immuno-
precipitated with a mouse monoclonal antibody anti-HA and
membranes were developed with a rabbit polyclonal anti-GFP.
Lysates (WCL) were also analyzed by western blotting to check the
input levels of HA-BCA2, Gag-GFP constructs and b-actin. V:
empty vector.
(TIF)
Figure S5 Effects of proteasomal and lysosomal inhib-
itors on BCA2 activity. (A) The effect of ALLN on the antiviral
activity of BCA2 was explored by knocking down endogenous
BCA2 in 293T cells treated with either DMSO or ALLN (25 mM),
and by analyzing the expression levels of HIV-1 Gag in cells and
p24 in virions. (B) Differences in the levels of Gag expression were
quantified by ImageJ64 software for cells treated with DMSO
(white) or ALLN (black), and the relative Gag expression was
calculated. (C) To determine if the increase in virus released
observed in HA-BCA2
+ cells treated with lysosomal inhibitors is
due to the specific inhibition of BCA2, the effects of these drugs on
virus release were evaluated in parental 293T cells and HA-BCA2-
expressing cells. Virus release was measured by HIV-1 p24
antigen-capture ELISA and expressed as the percentage of
maximal release, as described in the material and methods
section. (D) To evaluate the role of Rab7 in the mechanism of
restriction by BCA2, virus release assays were performed in the
presence of a dominant-negative mutant of Rab7A (Rab7 N125I).
Virus release was measured by HIV-1 p24 and SIV p27 antigen-
capture ELISA and expressed as the percentage of maximal
release in the absence of HA-BCA2. Error bars represent the
mean and standard deviation of independent experiments.
(TIF)
Figure S6 BCA2 leads to the accumulation of HIV-1 Gag
to TGN46-negative compartments. 293T cells were co-
transfected with constructs coding for HIV-1 NL4-3 proviral DNA
and HA-BCA2. Cells were stained for p24 (green), HA-BCA2
(blue) and the cellular marker TGN46 (red). White scale bar
corresponds to 10 mm.
(TIF)
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